Main Article Content


Background: Osteoarthritis (OA) is the most common musculoskeletal disease. World Health Organization (WHO) estimates that 10% of the aged over 60 year population have this disease. The aim of OA treatment is to reduce pain, which is the most OA patients chief
complaint. People in Indonesia are very interested in use of herbal therapies from original traditional plant to treat pain now, one of the traditional plants that are known have
a benefit is Phaleria macrocarpa or Mahkota Dewa fruit. Phaleria macrocarpa has been shown to decrease the degree of inflammation of OA animal model experiments. In order to know what is the effect of this fruit extract to reduce degrees of pain and change the levels of IL-1, IL-6, TNF-α in the blood as the marker of inflammation of patients with knee OA, and what is the effects to liver, kidney and haematology in the Indonesian population has
not been investigated 

Methods: The research method is an experimental study and the research design is PROBE (Prospective Randomized Open End Blinded Evaluation), to evaluate the efficacy of the extract Mahkota Dewa fruit (Phaleria macrocarpa fructus) 330 mg (Super Mahkota POM
TR 053 345 491) compared to meloxicam 7.5 mg in patients with knee osteoarthritis. The study population was outpatients with knee OA at Rheumatology Clinic Dr Hasan Sadikin Hospital Bandung. Patients are given Phaleria macrocarpa 330 mg or meloxicam 7.5 mg once a day for 14 days. Observations were made to evaluate the degree of pain as measured by VAS and Lequesne index at day 0, day 14 and measured again at day 28,
after they are not taking the extract anymore.

Results: Phaleria macrocarpa 330 mg is equal to meloxicam 7.5 mg in reducing the degree of pain as measured by VAS (p=0.78) and the Lequesne index (p=0.51). Our finding, t here is no effect of decreasing the proinflammatory cytokine IL-1 (p=0.72), IL-6
(p=0.53) and TNF-α (p=0.07) in the blood of both groups. Safety analysis shown that this extract is safe for consumption.

Conclusions: Phaleria macrocarpa 330 mg equal to meloxicam 7.5 mg in reducing the degree of pain however there is no effect on reducing proinflammatory cytokines in the blood of OA patients who had received therapy for 14 days in both groups. There is no adverse effects found on hematological, liver function and kidney function after consumption this plant’s fruit extract.

Keywords: osteoarthritis, mahkota dewa, phaleria macrocarpa

Article Details

How to Cite
Rahmadi, A. R., Dewi, S., Nawawi, A., Adnyana, I. K., & Wachjudi, R. G. (2018). Effectivity and safety of mahkota dewa fruit extract compared to meloxicam (phaleria macrocarpa fructus) on osteoarthritis. Indonesian Journal of Rheumatology, 8(1).


  1. Symmons D, Mathers C, Pfleger B. Global Burden of Osteoathritis in the Year 2000. WHO: Geneva; 2000.
  2. Aigner T, Schmitz N. Pathogenesis and Pathology of Osteoarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinbaltt ME, Weisman MH, editors. Rheumatology. 5th ed. MoSBy Elsevier: Philadelphia; 2011. P.1741-60.
  3. WHO Scientific Group. The burden of musculoskeletal condition at the start of the new millennium: WHO Technical Report Series. Geneva: WHO; 2010.
  4. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99
  5. Kopec JA, Rahman MM, Berthelot JM, Petit CL, Aghajanian J, Sayre EC, et al. Descriptive epidemiology of osteoarthritis in British Columbia, Canada. J Rheumatol 2007 ;34(2): 386-93.
  6. Dewi S, Wachjudi RG, Pramudiyo R. Profil Pasien di Klinik Reumatologi RS Dr. Hasan Sadikin Bandung tahun 2007: Temu Ilmiah Reumatologi. Jakarta; 2008.
  7. Hamik J, Rahmadi AR, Dewi S, Hamijoyo L, Wachjudi RG, Pramudiyo R. Profil Pasien Rawat Jalan di Klinik Reumatologi RSHS Bandung tahun 2011. Rematologi Klinik. Bandung; 2012.
  8. Vidyaniati P, Pramudiyo R Prevalensi Penyakit Reumatik di Poliklinik Reumatologi RSHS Bulan Januari – Desember 2012: Temu Ilmiah Reumatologi. Jakarta; 2013
  9. Sharm L. Epidemiology of osteoarthritis. In: Moskowitz R L, Howell DS, Setman DR, editors. Osteoarthritis diagnosis and medical/surgical management. 3rd ed. Philadelphia: WB Saunders; 2001. P.3-27
  10. Centers for Disease Control and Prevention. Estimated number of US population with physician-diagnosed osteoarthritis, 1990. Atlanta: Center for Disease Control and Prevention; 1995.
  11. Barr A, Conaghan PG. Osteoarthritis : a holistic approach. Clin Med (Lond) 2012;12(2):153-5.
  12. Haq I, Murphy E, Darce J. Osteoarthritis. Postgrad Med J 2003;79:377-83.
  13. Altman RD. Clinical features of osteoarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinbaltt ME, Weisman MH, editors. Rheumatology. 5th ed. MoSBy Elsevier: philadelphia ; 2011. P.1723-30.
  14. Ausiello JC, Stafford RS. Trends in medication use for osteoarthritis treatment. J Rheumatol 2002;29:999-1005.
  15. Tanna S. Osteoarthritis – opportunities to address pharmaceutical gaps: priority medicines for Europe and the world: A Public Health Approach to Innovation. 2004.
  16. Dougados M, Hochberg MC. Management of Osteoarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinbaltt ME, Weisman MH, editors. Rheumatology. 5th ed. MoSBy Elsevier: Philadelphia; 2011. P.1793-8.
  17. Penninx BW, Abbas H, Ambrosius W, Nicklas BJ, Davis C, Messier SP, et al. Inflammatory markers and physical function among older adults with knee osteoarthritis. J Rheumatol 2004;31(10):2027-31.
  18. Vlad SC, Neogi T, Aliabadi P, Fontes JDT, Felson DT. No association between Markers of Inflammation and Osteoarthritis of the Hands and Knees. J Rheumatol 2011;38(8):1665-70.
  19. Ditjen POM. Inventaris Tanaman Obat Indonesia. 5th ed. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia; 1999. P.147-148
  20. Harmanto N. Mahkota Dewa obat Pusaka Para Dewa. Jakarta: PT Agromedia Pustaka; 2002. P.7-21,27-9.
  21. Nawawi A, Suwendar, Ana UH, Deden S. Antiinflammatory and analgesic effect of mahkota dewa [Phaleria macrocarpa (Sceff.) boerl fruit. In: 4th Malaysian pharmaceutical Society Pharmacy Scientific Conference 2004. Kuala Lumpur: 2004.
  22. Adnyana IK, Nawawi A, Fisheri N, Linda, Hayati. Antiarthritic effect of
  23. ethanol extract of Phaleria macrocarpa (Scheff.) boerl fruits on collageninduced arthritic rats. In: International Seminar on harmaceutics. Bandung: 2007.
  24. Hakim RW. Elusidasi Struktur dan Uji Aktivitas Biologi Isolat Utama Buah Mahkota Dewa (Phaleria macrocarpa (Scheff.) Boerl. Bandung: Departemen Farmasi FMIPA ITB, 2004. P.7-22. Skripsi.
  25. Mariani R. Telaah Kandungan Kimia dan Aktivitas Antiradang Buah Mahkota Dewa (Phaleria macrocarpa (Scheff.) Boerl.Bandung: Departemen Farmasi FMIPA ITB, 2005. P.29-30. Thesis.
  26. Melori I. Uji Efek Antipirai Ekstrak Etanol Buah Mahkota Dewa (Phaleria macrocarpa (Scheff.) Boerl pada Tikus Jantan Galur Wistar. Bandung: Departemen Farmasi FMIPA ITB, 2006. P.4-6. Skripsi.
  27. Oshimi, Shiori, et al. Studies on the constituents from the fruits of Phaleria macrocarpa. J Nat Med 2008:62(2):207-10. doi: 10.1007/s11418-007-0209-9. 27. Zhang YB, Xu XJ, Liu HM. Chemical constituents from mahkota dewa. J Asian Nat Prod Res 2006;8(1-2):119-23.
  28. Nelson AE, Jordan JM. Osteoarthritis: Epidemiology and Clasification. In: Hochberg MC, Silman AJ, Smolen JS, Weinbaltt ME, Weisman MH, editors. Rheumatology. 5th ed. Philadelphia: MoSBy Elsevier; 2011. P.1709-16
  29. Croft P. The epidemiology of osteoarthritis : Manchester and beyond. Rheumatology (Oxford) 2005;44 Suppl 4, iv27-iv32.
  30. Felson DT, Zhang Y. Local and systemic risk factor for incidence and prognosis of OA. In: Hochberg MC, Silman AJ, Smolen JS, Weinbaltt ME, Weisman MH, editors. Rheumatology. 5th ed. Philadelphia: MoSBy Elsevier; 2011. P.1717-22
  31. Lauder SN, Carty SM, Carpenter CE, Hill RJ, Talamas F, Bondeson J, et al. Interleukin 1β induced activation of nuclear factor-κb can be inhibited by novel pharmacological agents in osteoarthritis. Rheumatology (Oxford)2007;46(5):752-8
  32. Williams RO, Mutafchieva LM, Feldmann M, Maini RN. Evaluation of TNF-α and IL-1 blockade in collagen induced arthritis and comparison with combined anti TNF-α / anti CD4 therapy. J Immunol 2000; 165(12): 7240-5.
  33. Kagari T, Doi H, Shimozato T. The importance of IL-1β and TNF-α and the noninvolvement of IL-6, in the development of monoclonal antibodyinduced arthritis. J Immunol 2002;169(3):1459-66.
  34. Joosten LAB, Helsen MMA, Saxne T, Van de Loo FAJ, Heinegard D, Van den Berg B. IL-1β blockade prevent cartilage and Bone Destruction in murine type II collagen induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol 1999;163(9):5049-55.
  35. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly: The framingham osteoarthritis study. Arthritis Rheum 1987;30:914-18
  36. Lewthwaire J, Blake S, Hardingham T, Foulkes R, Stephens S, Chaplin L, et al. Role of TNF-α in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNF-α neutralising monoclonal antibodies. Ann Rheum Dis 1995;54(5):366-74.
  37. Lauder SN, Carty M, Carpenter CE, Hill RJ, Tahumas F, Bondeson J, Brennan P, et al. Interleukin 1β induced activation of nuclear factor- κb can be inhibited by novel pharmacological agents in osteoarthritis. Rheumatology 2007;46:752-8.
  38. Wenham CYJ, Conaghan PG. The Role of Synovitis in Osteoarthritis. Ther Adv Musculoskel Dis 2010;6:349-59.
  39. Beni MJ, Veale, Gerald OF, Van den Berg WB, Bresnihan B. Synovial tissue inflamation in early and late osteoarthritis. Ann Rheum Dis 2005;64:1263-7.
  40. Benito MJ, Veale DJ, FitzGerald O, Van den Berg WB, Bresnihan B. Synovial tissue inflamation in early and late osteoarthritis. Ann Rheum Dis 2005;64:1263-7.
  41. Roemer FW. Plain radiography and magnetic resonance imaging diagnostic in osteoarthritis: validated staging and scoring. J Bone Joint Surg Am 2009;91[Suppl 1]:54-62.
  42. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Clasification of osteoarthritis of the knee. Diagnostic and therapeutic criteria, committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
  43. Von Korff M, Deyo RA, Cherkin D, Barlow SF. Back Pain in Primary Care. Spine 1993;855-62.
  44. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severitry for osteoatrthritis of the hip and knee. Validation value in comparison with other assessment tests. Scan J Rheumatol 1987;65:85-9.
  45. Rodrigues LAG, Hernandez-Diaz S. The risk of upper gastrointestinal complication associated with nonsteroidal anti-inflamatory drugs, glucocorticoids, acetaminophen, and combination of this agents. Artritis Res 2001;3:98-101.
  46. Akhtar N, Haqqi TM. Current nutraceuticals in the management of osteoarthritis : a review. Ther Adv Musculoskelet Dis 2012;4(3):181-207.
  47. Griffin MR, Ray WA, Schafener W. Nonsteroidal anti-inflamatory drug use and death from peptic ulcer in eldery person. Ann Intern Med 1988;109:359-63.
  48. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflamatory drug-associated gastropathy incidence and risk factor models. Am J Med 1991;91:213-22.
  49. Zohling J, Marc LM, Lapsley H, Cross M, Tribe M, Brooks P. Use of complementary medicines for osteoartrhritis: a prospective study. Ann Rheum Dis 2004;63:549-54.
  50. MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet 1996;347:569-73.
  51. Ramsey SD, Spencer AC, Topolsky TD, Belza B, Patrick DL. Use of alternative therapies by older adults with osteoarthritis. Arth Care Res 2001;45:222-7.
  52. Rao JK, Mihaliak K, Bradley J, Tierney WM, Weinberger M. Use of complementary therapies for arthritis among patients of rheumatologist. Ann Intern Med 1999; 131:409-16.
  53. Boisset M, Fitzcharles MA. Alternative medicine use by rheumatology patient in a universal health care setting. J Rheumatol 1993;21:148-52.
  54. Guo R, Canter PH, Ernst E. A systematic review of randomized clinical trials of individualized herbal medicine in any indication. Postgrad Med J 2007;83:633-7.
  55. Long L, Soeken R, Ernst E. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology 2001;40: 779-93.
  56. Canter PH, Wider B, Ernst E. The antioxidant vitamins A, C, E and Selenium in the treatment of arthritis: a systematic review of randomized clinical trial. Rheumatology 2007;46(8):1223-33.
  57. Bae SC, Jung WJ, Lee EJ, Yu R, Sung MK. Effects of antioxidant supplements intervention on the level of plasma inflammatory molecules and disease severity of rheumatoid arthritis patients. J Am Coll Nutr 2009;1:56-62.
  58. Stannus OP, Jones G, Blizzard L, Cicutinni FM, Ding C. Associations between serum levels of inflammatory markers and change in knee pain over 5 years in older adults: a prospective cohort study. Ann Rheum Dis 2013;72:535-40.
  59. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, et al. Patients Preference for Placebo, Acetaminophen (paracetamol), or Celecoxib efficacy studies (PACES): two randomized, double blind, placebo controled, crossover clinical trial in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004;63:931-39.
  60. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: Meta analysis of randomized controled trial. Ann Rheumm Dis 2008;67:1716-23.
  61. Fernandes L, Hagen KB, Bijlsma JWJ, Andreassen O, ChristensenP, Conaghan PG, et al. EULAR recommendations for the nonpharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 2013;0:1-11.